Fluoxetine inhibits inflammatory response and bone loss in a rat model of ligature-induced periodontitis

Journal of Periodontology

Volumn 83, Issue 5, 2012, Pages 664-671

  Branco De Almeida, Luciana S ^a   Franco, Gilson C ^b   Castro, Myrella L ^a   Dos Santos, Juliana G ^b   Anbinder, Ana Lia ^c   Cortelli, Sheila C ^b   Kajiya, Mikihito ^d,e   Kawai, Toshihisa ^d,e   Rosalen, Pedro L ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF TAUBATÉ   (Brazil)

^c SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^d FORSYTH INSTITUTE   (United States)

^e HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

Bone resorption; Collagen; Fluoxetine; Inflammation; Periodontitis

Indexed keywords

AUTACOID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FIBRILLAR COLLAGEN; FLUOXETINE; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; SEROTONIN UPTAKE INHIBITOR;

ALVEOLAR BONE LOSS; ANIMAL; ARTICLE; BIOSYNTHESIS; DRUG ANTAGONISM; GINGIVA; LIGATION; MALE; METABOLISM; METHODOLOGY; PERIODONTITIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; RAT; TISSUE CULTURE TECHNIQUE; WISTAR RAT;

ALVEOLAR BONE LOSS; ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FIBRILLAR COLLAGENS; FLUOXETINE; GINGIVA; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; LIGATION; MALE; MATRIX METALLOPROTEINASE 9; NITRIC OXIDE SYNTHASE TYPE II; PERIODONTITIS; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS; TISSUE CULTURE TECHNIQUES;

EID: 84860431514     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2011.110370     Document Type: Article

References (40)

1. Kornman KS, Page RC, Tonetti MS. The host response to the microbial challenge in periodontitis: Assembling the players. Periodontol 2000 1997;14:33-53.
2. Han X, Kawai T, Taubman MA. Interference with immune-cell-mediated bone resorption in periodontal disease. Periodontol 2000 2007;45:76-94.
3. Lappin DF, Kjeldsen M, Sander L, Kinane DF. Inducible nitric oxide synthase expression in periodontitis. J Periodontal Res 2000;35:369-373.
4. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998;12:12-26.
5. Holzhausen M, Rossa Júnior C, Marcantonio Júnior E, Nassar PO, Spolidório DM, Spolidório LC. Effect of selective cyclooxygenase-2 inhibition on the development of ligature-induced periodontitis in rats. J Peri-odontol 2002;73:1030-1036.
6. Reddy MS, Geurs NC, Gunsolley JC. Periodontal host modulation with antiproteinase, anti-inflammatory, and bone-sparing agents. A systematic review. Ann Peri-odontol 2003;8:12-37.
7. Leitão RF, Ribeiro RA, Chaves HV, Rocha FA, Lima V, Brito GA. Nitric oxide synthase inhibition prevents alveolar bone resorption in experimental periodontitis in rats. J Periodontol 2005;76:956-963. (Pubitemid 40903838)
8. Calil HM. Fluoxetine: A suitable long-term treatment. J Clin Psychiatry 2001;62(Suppl. 22):24-29. (Pubitemid 32937582)
9. Yaron I, Shirazi I, Judovich R, Levartovsky D, Caspi D, Yaron M. Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum 1999;42:2561-2568. (Pubitemid 30327172)
10. Abdel-Salam OM, Nofal SM, El-Shenawy SM. Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat. Pharmacol Res 2003;48:157-165. (Pubitemid 36683164)
11. Roumestan C, Michel A, Bichon F, et al. Anti-inflammatory properties of desipramine and fluoxe-tine. Respir Res 2007;8:35.
12. Guemei AA, El Din NM, Baraka AM, El Said Darwish I. Do desipramine [10,11-dihydro-5-[3-(methylamino) propyl]-5H-dibenz[b,f]azepine monohydrochloride] and fluoxetine [N-methyl-3-phenyl-3-[4-(trifluoromethyl)- phenoxy]-propan-1-amine] ameliorate the extent of colonic damage induced by acetic acid in rats? J Pharmacol Exp Ther 2008;327:846-850.
13. Sacre S, Medghalchi M, Gregory B, Brennan F, Williams R. Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum 2010;62:683-693.
14. Bianchi M, Rossoni G, Sacerdote P, Panerai AE, Berti F. Effects of chlomipramine and fluoxetine on subcutaneous carrageenin-induced inflammation in the rat. Inflamm Res 1995;44:466-469.
15. Branco-de-Almeida LS, Kajiya M, Cardoso CR, et al. Selective serotonin reuptake inhibitors attenuate the antigen presentation from dendritic cells to effector T lymphocytes. FEMS Immunol Med Microbiol 2011; 62:283-294.
16. Irie K, Tomofuji T, Tamaki N, et al. Effects of ethanol consumption on periodontal inflammation in rats. J Dent Res 2008;87:456-460.
17. Rodini CO, Batista AC, Diońisio TJ, Santos CF, Cunha FQ, Lara VS. Morphologic evaluation and expression of matrix metalloproteinases-2 and 9 and nitric oxide during experimental periodontal disease in rat. J Mol Histol 2008;39:275-282.
18. Nociti FH Jr, Nogueira-Filho GR, Primo MT, et al. The influence of nicotine on the bone loss rate in ligature-induced periodontitis. A histometric study in rats. J Periodontol 2000;71:1460-1464.
19. Rich L, Whittaker P. Collagen and picrosirius red staining: A polarized light assessment of fibrillar hue and spatial distribution. Braz J Morphol Sci 2005;22: 97-104.
20. Forte LF, Cortelli SC, Cortelli JR, et al. Psychological stress has no association with salivary levels of beta-defensin 2 and beta-defensin 3. J Oral Pathol Med 2010;39:765-769.
21. Marques MR, dos Santos MC, da Silva AF, Nociti FH Jr, Barros SP. Parathyroid hormone administration may modulate periodontal tissue levels of interleukin-6, matrix metalloproteinase-2 and matrix metalloprotei-nase-9 in experimental periodontitis. J Periodontal Res 2009;44:744-750.
22. Graves DT, Fine D, Teng YT, Van Dyke TE, Hajishengallis G. The use of rodent models to investigate host-bacteria interactions related to peri-odontal diseases. J Clin Periodontol 2008;35:89-105.
23. Hou LT, Liu CM, Rossomando EF. Crevicular interleu-kin-1 beta in moderate and severe periodontitis patients and the effect of phase I periodontal treatment. J Clin Periodontol 1995;22:162-167.
24. McCauley LK, Nohutcu RM. Mediators of periodontal osseous destruction and remodeling: Principles and implications for diagnosis and therapy. J Periodontol 2002;73:1377-1391. (Pubitemid 35469686)
25. Schwartz Z, Goultschin J, Dean DD, Boyan BD. Mechanisms of alveolar bone destruction in peri-odontitis. Periodontol 2000 1997;14:158-172.
26. Offenbacher S, Heasman PA, Collins JG. Modulation of host PGE2 secretion as a determinant of periodontal disease expression. J Periodontol 1993; 64(Suppl. 5)432-444.
27. Jin Y, Lim CM, Kim SW, et al. Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. Brain Res 2009;1281:108-116.
28. Teng YT, Sodek J, McCulloch CA. Gingival crevicular fluid gelatinase and its relationship to periodontal disease in human subjects. J Periodontal Res 1992; 27:544-552.
29. Opdenakker G, Van den Steen PE, Van Damme J. Gelatinase B: A tuner and amplifier of immune functions. Trends Immunol 2001;22:571-579. (Pubitemid 33016405)
30. Benekareddy M, Mehrotra P, Kulkarni VA, Ramakrishnan P, Dias BG, Vaidya VA. Antidepressant treatments regulate matrix metalloproteinases-2 and-9 (MMP-2/MMP-9) and tissue inhibitors of the metalloproteinases (TIMPS 1-4) in the adult rat hippocampus. Synapse 2008;62:590-600. (Pubitemid 351951297)
31. Li XQ, Wang HM, Yang CG, Zhang XH, Han DD, Wang HL. Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in mono-crotaline-treated rats. Acta Pharmacol Sin 2011;32: 217-222.
32. Ha E, Jung KH, Choe BK, et al. Fluoxetine increases the nitric oxide production via nuclear factor kappa B-mediated pathway in BV2 murine microglial cells. Neurosci Lett 2006;397:185-189.
33. Roman A, Rogóz Z, Kubera M, Nawrat D, Nalepa I. Concomitant administration of fluoxetine and aman-tadine modulates the activity of peritoneal macro-phages of rats subjected to a forced swimming test. Pharmacol Rep 2009;61:1069-1077.
34. Bianchi M, Sacerdote P, Panerai AE. Fluoxetine reduces inflammatory edema in the rat: Involvement of the pituitary-adrenal axis. Eur J Pharmacol 1994;263: 81-84. (Pubitemid 24290256)
35. Diamond M, Kelly JP, Connor TJ. Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol 2006;16:481-490. (Pubitemid 44311000)
36. Zajecka J, Amsterdam JD, Quitkin FM, et al. Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J Clin Psychiatry 1999;60:389-394. (Pubitemid 29289727)
37. Serretti A, Mandelli L. Antidepressants and body weight: A comprehensive review and meta-analysis. J Clin Psychiatry 2010;71:1259-1272.
38. Gelfin Y, Gorfine M, Lerer B. Effect of clinical doses of fluoxetine on psychological variables in healthy volunteers. Am J Psychiatry 1998;155:290-292. (Pubitemid 28074298)
39. Bonne O, Krausz Y, Aharon Y, Gelfin Y, Chisin R, Lerer B. Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers. Psychopharmacology (Berl) 1999; 143:24-28. (Pubitemid 29189991)
40. Hartung HP, Kieseier BC. The role of matrix metal-loproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol 2000; 107:140-147. (Pubitemid 30347419)